B.1.617.2(Delta)与B.1.1.529(Omicron)变异株优势流行期实验室确诊SARS-CoV-2感染住院成人的临床特征与结局——加利福尼亚州一家医院,2021年7月15日至9月23日及2021年12月21日至2022年1月27日
回顾性提取加州一家学术医院Delta优势期339例和Omicron优势期737例≥18岁RT-PCR阳性住院成人的电子健康记录。Omicron期完全接种比例更高(39.6%对25.1%),接受COVID-19针对性治疗更少;ICU入住、有创机械通气和住院死亡更少,但按接种状态分层后ICU入住或有创机械通气无显著差异。Omicron期完全接种者住院死亡3.4%,低于Delta期10.6%。
要点
- Omicron优势期完全接种比例39.6%,高于Delta优势期25.1%。
- Omicron期ICU入住、有创机械通气和住院死亡更少,但按接种状态分层后ICU入住或有创机械通气无显著差异。
- Omicron期完全接种者住院死亡3.4%,低于Delta期10.6%;接种加强针者ICU入住和死亡可能性最低。
核心结论
- Omicron优势期住院成人中完全接种比例高于Delta优势期,接受COVID-19针对性治疗更少。
- Omicron优势期ICU入住、有创机械通气和住院死亡更少,但按接种状态分层后ICU入住或有创机械通气无显著差异。
- Omicron优势期完全接种者住院死亡3.4%,低于Delta优势期10.6%。
- Omicron优势期接种与较低ICU入住可能性相关,≥65岁成人中与较低住院死亡可能性相关,接种加强针者ICU入住和死亡可能性最低。
- Omicron优势期首批131例住院中19.8%被临床评估为非COVID-19病情入院,其年龄中位数38岁对67岁、至少接种一剂疫苗比例84.6%对61.0%。
研究设计与样本
- 回顾性从电子健康记录提取2021年7月15日至9月23日Delta优势期339例和2021年12月21日至2022年1月27日Omicron优势期737例≥18岁RT-PCR阳性住院成人的临床特征与结局。
- 研究地点为加利福尼亚州洛杉矶一家学术医院。
主要发现
- Omicron优势期完全接种比例39.6%,高于Delta优势期25.1%。
- Omicron优势期接受COVID-19针对性治疗的患者更少。
- Omicron优势期ICU入住、有创机械通气和住院死亡更少,但按接种状态分层后ICU入住或有创机械通气无显著差异。
- Omicron优势期完全接种者住院死亡3.4%,低于Delta优势期10.6%。
- Omicron优势期首批131例住院中19.8%被临床评估为非COVID-19病情入院,其年龄中位数38岁对67岁、至少接种一剂疫苗比例84.6%对61.0%。
临床怎么用
- 作者认为,尽管Omicron优势期约20%的SARS-CoV-2相关住院可能由非COVID-19病情驱动,大量住院仍对卫生系统造成压力。
- 作者认为,接种疫苗(包括为完全接种者接种加强针)对最小化SARS-CoV-2感染成人严重健康结局风险仍然关键。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In mid-December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, surpassed the B.1.617.2 (Delta) variant as the predominant strain in California.§ Initial reports suggest that the Omicron variant is more transmissible and resistant to vaccine neutralization but causes less severe illness compared with previous variants (1-3). To describe characteristics of patients hospitalized with SARS-CoV-2 infection during periods of Delta and Omicron predominance, clinical characteristics and outcomes were retrospectively abstracted from the electronic health records (EHRs) of adults aged ≥18 years with positive reverse transcription-polymerase chain reaction (RT-PCR) SARS-CoV-2 test results admitted to one academic hospital in Los Angeles, California, during July 15-September 23, 2021 (Delta predominant period, 339 patients) and December 21, 2021-January 27, 2022 (Omicron predominant period, 737 patients). Compared with patients during the period of Delta predominance, a higher proportion of adults admitted during Omicron predominance had received the final dose in a primary COVID-19 vaccination series (were fully vaccinated) (39.6% versus 25.1%), and fewer received COVID-19-directed therapies. Although fewer required intensive care unit (ICU) admission and invasive mechanical ventilation (IMV), and fewer died while hospitalized during Omicron predominance, there were no significant differences in ICU admission or IMV when stratified by vaccination status. Fewer fully vaccinated Omicron-period patients died while hospitalized (3.4%), compared with Delta-period patients (10.6%). Among Omicron-period patients, vaccination was associated with lower likelihood of ICU admission, and among adults aged ≥65 years, lower likelihood of death while hospitalized. Likelihood of ICU admission and death were lowest among adults who had received a booster dose. Among the first 131 Omicron-period hospitalizations, 19.8% of patients were clinically assessed as admitted for non-COVID-19 conditions. Compared with adults considered likely to have been admitted because of COVID-19, these patients were younger (median age = 38 versus 67 years) and more likely to have received at least one dose of a COVID-19 vaccine (84.6% versus 61.0%). Although 20% of SARS-CoV-2-associated hospitalizations during the period of Omicron predominance might be driven by non-COVID-19 conditions, large numbers of hospitalizations place a strain on health systems. Vaccination, including a booster dose for those who are fully vaccinated, remains critical to minimizing risk for severe health outcomes among adults with SARS-CoV-2 infection.
引用
- Modes ME, Directo MP, Melgar M, et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35143466. doi:10.15585/mmwr.mm7106e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。